Markets

Gilead's Kite, Arcellx Expand Partnership

November 15, 2023 — 06:57 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Kite, a Gilead Company (GILD) Wednesday announced expansion of its partnership with Arcellx, Inc. (ACLX) by investing in Arcellx's ACLX001 ARC-SparX program in multiple myeloma.

Arcellx will receive $200 million equity investment at $61.68 per share, and an upfront payment of $85 million in cash, which is expected to extend the company's cash runway into 2027.

In December 22, the companies have announced collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.

The companies have also expanded the scope of the collaboration for Arcellx's CART-ddBCMA to include lymphomas.

The transaction is expected to close around year-end 2023.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
GILD

Latest Articles
Data is currently not available